Biotech Values

[DewDiligence]

Late-Stage Products Looking for a Home

Criteria for inclusion:
a) Program has completed phase-2b or later and is non-partnered; AND
b) Company lacks the financial resources to commercialize the product on its own.

Edits: Updated notes field for Rhucin.

  
 Company  Product     Phase   Indication (notes)    
 =======  =======     =====   ==================    
 ARNA     Lorcaserin  NDA     Obesity    
 ARYX     Budiodarone 2B      Atrial Fibrillation  
 ARYX     Tecarfarin  3       VTE prevention (failed initial ph-3)  
 BPAX     Libigel     3       Female Sexual Desire Disorder    
 DYAX     Kalbitor    US app  acute HAE (seeking ex-US partner)    
 HNAB     Marqibo     2B      ALL (ENZN failed acc. approval in NHL) 
 JAV      Dyloject    NDA     Post-op pain (approved in UK)    
 JAV      Ketamine    3       Acute pain    
 OREX     Contrave    NDA     Obesity    
 OXGN     Zybrestat   3       Anaplastic thyroid cancer    
 MNKD     Afrezza     BLA     Diabetes (CRL rec’d 3/15/10)    
 Pharming Rhucin      BLA     HAE (CHMP decision expctd Jun 2010)    
 SOMX     Silenor     apprvd  Insomnia (low dose of generic doxepin)    
 SVNT     Krystexxa   BLA     Gout (response to CRL submtd 3/30/10)    
 VVUS     Qnexa       NDA     Obesity

Procedure for Updating Table

1. Copy the text in this post into a word processor.

2. Using a monospace font (e.g. Courier) to facilitate tabular
alignment, make your additions and modifications, inserting
them in the table in alphabetical order. NOTE: use spaces
rather than tab characters.

3. Add a brief note in the “Edits:” line atop the table to
describe your changes.

4. Insert the iHub formatting directives: Put [ pre ] at the
beginning of the table without the surrounding spaces, and
put [ /pre ] at the end of the table without the surrounding
spaces.

5. Post your text as a reply to this message.

Thank you for your cooperation.